title: [Prevention and treatment of major bleeding during anticoagulation].
abstract: To prevent major hemorrhage during anticoagulation, it is quite important to manage controllable risk factors such as hypertension, diabetes mellitus, smoking habit, and too much alcohol intake. It is also important to avoid dual antithrombotic therapy as long as possible, which increases severe bleeding events. For patients with major bleeding during anticoagulation, we should stop oral medication, stop bleeding by mechanical compression or surgical interventions, and maintain circulation blood volume and blood pressure by appropriate intravenous drip infusion. When intracranial hemorrhage happens, adequate treatment to suppress blood pressure should be provided. Administration of prothrombin complex concentrate (PCC) and vitamin K is effective for urgent reversal of anticoagulation by warfarin. The PCC may be also useful for that by novel oral anticoagulants.
authors.affiliation: Cerevrovascular Medicine and Neurology, Cerebrovascular Center, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yasaka
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Okada
mesh_terms: D000284:Administration, Oral; D000428:Alcohol Drinking; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects*; D002543:Cerebral Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D000069604:Dabigatran; D003920:Diabetes Mellitus; D004359:Drug Therapy, Combination; D005164:Factor IX / Q000008:administration & dosage; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D006973:Hypertension; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking; D014812:Vitamin K / Q000008:administration & dosage; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects*; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D005343:Fibrinolytic Agents; D015091:beta-Alanine; D014812:Vitamin K; D014859:Warfarin; D005164:Factor IX; D000069604:Dabigatran